key: cord-0893481-x92bxifa authors: Lodigiani, Corrado; Iapichino, Giacomo; Carenzo, Luca; Cecconi, Maurizio; Ferrazzi, Paola; Sebastian, Tim; Kucher, Nils; Studt, Jan-Dirk; Sacco, Clara; Alexia, Bertuzzi; Sandri, Maria Teresa; Barco, Stefano title: Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy date: 2020-04-23 journal: Thromb Res DOI: 10.1016/j.thromres.2020.04.024 sha: 08767d008d8720813b015083d5c3db8e7309ffc3 doc_id: 893481 cord_uid: x92bxifa Abstract Background Few data are available on the rate and characteristics of thromboembolic complications in hospitalized patients with COVID-19. Methods We studied consecutive symptomatic patients with laboratory-proven COVID-19 admitted to a university hospital in Milan, Italy (13.02.2020–10.04.2020). The primary outcome was any thromboembolic complication, including venous thromboembolism (VTE), ischemic stroke, and acute coronary syndrome (ACS)/myocardial infarction (MI). Secondary outcome was overt disseminated intravascular coagulation (DIC). Results We included 388 patients (median age 66 years, 68% men, 16% requiring intensive care [ICU]). Thromboprophylaxis was used in 100% of ICU patients and 75% of those on the general ward. Thromboembolic events occurred in 28 (7.7% of closed cases; 95%CI 5.4%–11.0%), corresponding to a cumulative rate of 21% (27.6% ICU, 6.6% general ward). Half of the thromboembolic events were diagnosed within 24 h of hospital admission. Forty-four patients underwent VTE imaging tests and VTE was confirmed in 16 (36%). Computed tomography pulmonary angiography (CTPA) was performed in 30 patients, corresponding to 7.7% of total, and pulmonary embolism was confirmed in 10 (33% of CTPA). The rate of ischemic stroke and ACS/MI was 2.5% and 1.1%, respectively. Overt DIC was present in 8 (2.2%) patients. Conclusions The high number of arterial and, in particular, venous thromboembolic events diagnosed within 24 h of admission and the high rate of positive VTE imaging tests among the few COVID-19 patients tested suggest that there is an urgent need to improve specific VTE diagnostic strategies and investigate the efficacy and safety of thromboprophylaxis in ambulatory COVID-19 patients. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) causing coronavirus disease 2019 (COVID-19) has led to an unprecedented global health crisis. To date, more than 160,000 COVID-19-related deaths have been confirmed. Case fatality rate has been estimated to be as high as 15% in some countries. (1) Clinical manifestations are absent or mild in a substantial proportion of subjects who test positive for SARS-CoV2. Bilateral pneumonia is the main finding in hospitalized patients and at least 5% initially present in serious condition, requiring advanced medical support or intensive care. (1, 2) Bilateral pneumonia, systemic inflammation, endothelial dysfunction, coagulation activation, acute respiratory distress syndrome, and multiorgan failure have been described as key features of severe COVID-19. (3) (4) (5) (6) (7) (8) Signs of myocardial injury are present in at least one quarter of severe cases. (2, 9) It has been postulated that the high mortality observed among COVID-19 patients may be partly due to unrecognized pulmonary embolism (PE) and pulmonary in situ thrombosis. Estimates of the risk of arterial and, in particular, venous thromboembolic complications are still preliminary and depend on local diagnostic and pharmacological preventive strategies. (10, 11) Better understanding of COVID-19-related thromboembolic risk will help to optimize diagnostic strategies and guide the design and conduction of randomized controlled trials on VTE prevention. In this study, we described the rate and characteristics of venous and arterial thromboembolic complications in consecutive patients who have been admitted to a large academic hospital in Milan, Italy, since the beginning of the outbreak. February 2020. The study was approved by the institutional ethical committee and patients gave standard written consent to the use of their data. We aimed to describe the rate of venous and arterial thromboembolic complications in hospitalized patients with COVID-19. Electronic medical records served as source data for the collection of demographics, clinical, laboratory, treatment, and outcome data, which were extracted in an anonymized form by two physicians. Potential disagreements concerning the interpretation of the findings was done in collaboration with a third physician. The primary outcome was a composite of venous and arterial thromboembolic events, encompassing VTE and other cardiovascular events. VTE included pulmonary embolism (PE) and deep vein thrombosis (DVT) diagnosed by accepted imaging tests. During the period considered for the present analysis, no VTE screening strategy among COVID-19 patients was in place at the study site: VTE imaging tests were performed in subjects with signs or symptoms of DVT or with an unexplained clinical worsening of the respiratory function, primarily assessed using the paO 2 /FIO 2 ratio, or a rapid increase of D-dimer levels. calculate the International Society on Thrombosis and Haemostasis (ISTH) score for overt DIC, which was considered present if the score was 5 or greater (12) . We described the characteristics of our study population using counts and percentages for categorical variables. We used appropriate measures of central tendency and dispersion to describe continuous variables. The rate of events was accompanied by 95% confidence interval (95%CI) and calculated for closed cases, defined as patients discharged, or dead, or (for analysis on thromboembolic complications) diagnosed with a thromboembolic event. Cumulative rates were calculated for the whole study population, including patients still hospitalized. A univariate logistic regression was performed to ascertain the effects of age on the likelihood that patients died during hospitalization: the probability of death across age was depicted visually. Missing values have been reported for each variable, if any. JASP v.0.11.1 and SPSS v. 25.0 served for data analysis. We extracted data from 388 consecutive patients with laboratory-proven COVID-19 admitted between 13.02.2020 and 10.04.2020. The median age was 66 (Q1-Q3 55-85) years and 264 (68%) were men. A total of 375 (97%) patients were tested for SARS-CoV2 before or on the day of initial hospital admission. Eight (2.1%) patients were tested during the first week of hospitalization and six (1.5%) between week 2-4 of hospitalization. Patients admitted to hospital during the very first days of the outbreak belonged to the latter group. We recorded a total of 92 in-hospital deaths, corresponding to an in-hospital mortality rate of 26% among closed cases. Deaths occurred after a median of 7 (Q1-Q3 4-12) days from hospital admission. Figure 1 depicts the probability of in-hospital death across age (Odds Ratio 1.10 per year increase, 95%CI 1.07-1.13). Variations in D-dimer levels among survivors and non-survivors are displayed in Table 2 . All ICU patients received thromboprophylaxis with low-molecular-weight heparin: the dosage was weight-adjusted in 17 patients and therapeutic in two patients on ambulatory treatment with direct oral anticoagulants. A total of 246 (75%) patients admitted to general wards received initial in-hospital thromboprophylaxis: a prophylactic dosage was used in 133 (41%) patients, 67 (21%) were treated with intermediate-dosage thromboprophylaxis, and 74 (23%) received therapeutic-dose anticoagulation, including 22 who continued ambulatory treatment for atrial fibrillation or prior VTE. Thromboembolic events occurred in 28 of 362 closed cases for a rate of 7.7% (95%CI 5.4%-11.0%) among closed cases, corresponding to a cumulative rate of 21.0%. Eight events occurred in ICU patients (16.7%; 95%CI 8.7%-29.6%) corresponding to a cumulative rate of 27.6%. Twenty events occurred in patients on the general ward (6.4%; 95%CI 4.2%-9.6%) corresponding to a cumulative rate of 6.6% ( Table 3) . We reported a detailed description of all thromboembolic events in Table 4 . Ischemic stroke was diagnosed in 9 (2.5%) patients: 3 were on the ICU and 6 of those on the general ward. One patient developed both stroke and acute PE. In 6 (67%) patients, stroke was the primary reason for hospitalization. Acute coronary syndrome/myocardial infarction was diagnosed in four (1.1%) patients, of whom 3 were on the ICU and one of those on the general ward. This represented the primary reasons for hospitalization in 3 (75%) patients. A total of 8 (2.1%) patients met the laboratory criteria for overt DIC. Six (75%) patients were men, one (13%) was required intensive care, four (50%) had solid or hematological cancer. No bleeding complications were recorded. Two (25%) patients had thromboembolic events (DVT, ischemic stroke); Table 4 . Seven (88%) patients with overt DIC died during hospitalization. We performed a comprehensive analysis of the rate, timing, and characteristics of venous According to a Chinese study, the prevalence of VTE was 25% with routine VTE screening, although details on the type and timing of screening were not provided. The burden of thromboembolic complications in these patients is unknown. Our data, which represent conditional probabilities and should therefore be carefully interpreted, suggest that this may represent an underestimated, large-scale issue requiring rapid answers. A randomized controlled trial, the OVID trial, is being planned to study whether prophylactic- Worldometer COVID-19 Data. Available at Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Prominent changes in blood coagulation of patients with SARS-CoV-2 infection Clinical features of patients infected with 2019 novel coronavirus in Wuhan Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Endothelial cell infection and endotheliitis in COVID-19 Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group